St. Jude Medical (NYSE: STJ) was the recipient of a ratings changes during the seven days:

  • St. Jude Medical had its “buy” rating reaffirmed by analysts at Lazard. They now have a $46.00 price target on the stock.
  • St. Jude Medical had its “sector perform” rating reaffirmed by analysts at RBC Capital. They now have a $37.00 price target on the stock.
  • St. Jude Medical had its “neutral” rating reaffirmed by analysts at Zacks. They now have a $42.00 price target on the stock.
  • St. Jude Medical was downgraded by analysts at Credit Suisse from an “outperform” rating to a “neutral” rating. They now have a $43.00 price target on the stock, down previously from $45.00. They wrote, “Our downgrade is driven by the RESPECT result and the recent FDA form 483 that could result in a Warning Letter for the CRM division. While we believe that DURATA will be exonerated, beginning with the independent analysis in next month’s Product Performance Report, perceived regulatory risk and skepticism regarding the pipeline (given STJ’s misplaced focus of the investor base on the trial) will likely offset fading Durata concerns. Upside risk could stem from an optically improving ICD market (due to the lapping of destocking) and/or resurrection of CardioMEMS. There are no changes to our estimates (which did not include any PFO numbers).”
  • St. Jude Medical had its “overweight” rating reaffirmed by analysts at JPMorgan Chase. They now have a $47.00 price target on the stock.

Shares of St. Jude Medical, Inc. opened at 38.29 on Monday. St. Jude Medical, Inc. has a 52 week low of $32.13 and a 52 week high of $44.80. The company has a market cap of $12.100 billion and a P/E ratio of 16.07.

St. Jude Medical, Inc. (St. Jude) develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.